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INTRODUCTION
Human rhinovirus (HRV) was first isolated in 1956 from a pa-
tient with a common cold. Over the next 50 years, a total of 100 
serotypes were defined using viral culture techniques.
1 In the 
past 20 years, the development of more sensitive nucleic-acid 
based diagnosis methods has led to new insights into the ge-
netic diversity of HRV, and the role of these viruses in respirato-
ry disease. For example, various studies beginning in 2006 have 
detected multiple members of a whole new species of HRV.
1 In 
addition, HRV infections were found to be closely related to 
wheezing illnesses in infants and young children,
2,3 and exacer-
bations of chronic respiratory diseases such as asthma, chronic 
obstructive pulmonary diseases, and cystic fibrosis.
4,5 Despite 
the extensive clinical evidence linking HRV infection to lower 
respiratory illness, the precise role of HRV as a lower airway 
pathogen is still controversial, mainly because HRV are so often 
recovered in individuals who have very mild illness or are as-
ymptomatic. In this review, new advances in understanding the 
link between HRV and asthma will be discussed.
 
PROPERTIES OF HRVS
HRV are 7.2 kb positive-sense single stranded RNA viruses that 
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belong to the Picornaviridae family. ‘Pico’ is the Latin root for 
‘small’ , and so the literal translation of Pico-rna-viridae is “small-
RNA-virus” . Although the previous classification system listed a 
separate Rhinovirus genus, the revised classification system has 
HRV as three separate species in the Enterovirusgenus.
6,7 There 
are more than 100 classical HRV serotypes that were detected 
initially by culture, and these include the closely related viruses 
HRV-1A and HRV-1B, HRV-2 to HRV-100 and HRV-Hanks.
8
The capsid of HRV is an icosahedron that is formed by 4 cap-
sid proteins: VP1, VP2, VP3, and VP4. HRV are now classified 
into A and B species viruses according to the nucleotide se-
quence that encodes the VP4/VP2 capsid protein. The first 
HRV-C species virus was identified in 2006 by Arden et al.
1, and 
close to 50 members of this species have been defined based 
on partial genetic sequencing. Epidemiologic studies indicate 
that HRV-C viruses are often detected in infants and young chil-
dren with symptoms of lower respiratory illness,
6,7,9 and a study 
of Australian children suggests that HRV-C viruses are found 
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more often than other HRV in children with exacerbations of 
asthma.
10 These findings raise the possibility that HRV-C may 
be more virulent than other HRV. As additional full length se-
quence information becomes available, it is possible that some 
viruses may be classified as a separate HRV-D species based on 
genetic differences.
8 HRV can also be grouped according to the 
‘receptor’ that is used by HRV to invade host cells. More than 
90% of the HRV use human intercellular adhesion molecule 
(ICAM-1, CD54) as their receptor and are known as ‘major 
group’ viruses (e.g. HRV-A16).
11 Approximately 10% of the RVs 
bind to members of the low-density lipoprotein receptor (LDLR) 
family, and are known as ‘minor group’ viruses (e.g. HRV-A1). 
Notably, HRV-C types bind to a distinct receptor that has not 
yet been identified.
6,8
Recently, complete genome sequences were determined for 
canonical HRV-A and -B species viruses from the American 
Type Culture Collection (ATCC), as well as several field iso-
lates.
11 These sequences were used to draw a phylogenetic tree 
for HRV, and also provided new insights into similarities and 
differences among the three HRV species. For example, there 
were species-specific sequences in a pyrimidine-rich region lo-
cated next to the cloverleaf structure in the 5’-untranslated re-
gion (5’UTR). In addition, there was clear evidence that some 
HRV genomes were the product of recombination between two 
parental HRV types. Continued work on HRV genomics may 
provide new insights into mechanisms of pathogenicity, and 
possible identify new targets for medical therapies.
6
 
EPIDEMIOLOGY OF HRV INFECTION
HRV infection is the most common cause of respiratory illness 
in children and adults of all ages.
12 HRV infections have long 
been known to occur most frequently during the spring and au-
tumn seasons.
13 A recent study obtained weekly samples from 
children during several seasons, and found that HRV infections 
continue to be quite common in the summer and winter sea-
sons.
12 HRV infections also can be asymptomatic; a review of 
several studies reveals that 12%-22% of samples acquired from 
asymptomatic children were positive for HRV,
4,14 and rates of 
asymptomatic infection can be even higher in young infants.
15 
Similar findings have been reported for seronegative adult vol-
unteers after experimental inoculation with HRV-A16.
10 These 
studies also demonstrate that HRV infections have a relatively 
short latency period (1-3 days) between inoculation and the 
onset of symptoms. Most HRV illnesses last 3-7 days, and the 
intensity of viral shedding roughly correlates with the intensity 
of symptoms. Low level shedding of HRV can continue for 1-2 
weeks after symptom resolution, and even longer in some in-
fants.
16 HRV does not cause chronic infection in immune com-
petent individuals.
MOUSE MODEL OF HRV INFECTION
Until recently, it was generally accepted that HRV infections 
were limited to the chimpanzee and human, and did not occur 
in the mouse. The reason for this species limitation is that HRV 
does not bind to murine ICAM-1. In contrast, minor group HRV 
can bind to murine LDLR, but replication was found to be very 
limited unless the mouse was immunosuppressed. An improved 
mouse model of HRV infection was reported in 2008.
17 Bartlett 
et al.
17 used a transgenic mouse that expressed human ICAM-1, 
and successfully produced HRV infections that mimicked many 
features of human HRV infection. In addition, infection of mice 
with the minor-group virus HRV-1B was also achieved by in-
creasing the viral inoculum.
17 In the mouse, HRV infection in-
duced respiratory tract neutrophilic inflammation, and pro-
duction of interferons and neutrophil chemokines. Viral repli-
cation was also documented, although the duration is short (24 
hours or less) compared to human infection. Additional studies 
have demonstrated that in animals sensitized to ovalbumin, 
HRV infection augmented eosinophilic airway inflammation, 
increased production of Th2 cytokines, and induced airway hy-
perreactivity.
17 Although the mouse model has some limita-
tions, these early findings suggest that it may be helpful in de-
fining HRV pathogenesis and mechanisms for HRV-induced 
exacerbations of asthma.
 
HRV-INDUCED ANTIVIRAL AND INFLAMMATORY 
RESPONSES
Cells recruited to the airway are activated by the infection and 
secrete a variety of cytokines and mediators that may have anti-
viral effects, but also contribute to airway inflammation and re-
spiratory symptoms.
18,19 Activated macrophages can secrete 
IFN-α, IFN-γ, TNF-α, MIP-1α, IL-1, and IL-8. Neutrophil num-
bers increase rapidly during the acute phase of a cold, and these 
cells secrete elastase, cathepsin G, and neutrophil proteinase 3. 
Eosinophils generally do not increase in number during the 
acute cold, but increases in eosinophils have been reported 
during recovery. Notably, eosinophilic inflammation has been 
linked to an increased risk of virus-induced exacerbation, and 
increased severity of experimentally-induced colds (Figure).
10,20
HRV is recognized by several pattern recognition receptors, 
including toll-like receptor (TLR)-3, TLR-7/8, retinoic acid in-
ducible gene 1 protein (RIG-1) and melanoma differentiation-
associated gene 5 (MDA-5).
18 Following binding to receptors on 
the cell membrane, HRV is internalized into endosomes, and 
then releases RNA into the cell cytoplasm in a process known 
as “uncoating” . RNA is recognized through several different 
pathways. TLR-7 and TLR-8 are expressed on the endosomal 
membrane and bind single-stranded RNA. These receptors ac-
tivate several intracellular signaling proteins including myeloid 
differentiation primary response gene-88, and a cascade of pro-Kim et al.
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teins including TNF receptor associated factor (TRAF)-6, inter-
leukin-1 receptor-associated kinase (IRAK)-1, IRAK-4 and inter-
feron regulatory factor (IRF)-7.
21,22 In addition, double-stranded 
RNA produced during viral replication can activate TLR-3 on 
the endosomal membrane, leading to activation of TRIF, IKKγ, 
IKKβ, IKKα, and ultimately NF-κB. In the cytoplasm, HRV RNA 
binds to and activates RIG-1 or by MDA-5. These “RNA helicas-
es” set off a similar signaling cascade including MAVS, IKKγ, 
IKKβ, IKKα, TBK-1/IKKε, and IRF-3. The net result of activation 
of RNA-sensing proteins is the production of interferons and 
other effector molecules with antiviral properties. HRV-infect-
ed epithelial cells can also secrete a variety of acute phase cyto-
kines (e.g. TNF-α, IL-6), chemokines (e.g. IL-8, RANTES, MIP-
1α, and IP-10) and growth factors (G-CSF, GM-CSF) that initiate 
the respiratory tract inflammatory response, and recruit and 
activate cellular inflammatory responses.
21,22
ROLES OF HRV IN THE DEVELOPMENT OF ASTHMA
More severe viral illnesses in infancy have been linked to in-
creased risk of developing asthma. For example, children who 
were diagnosed with lower respiratory tract infection by a phy-
sician before 3 years old were more likely to have asthma be-
tween 6-11 years of age.
23,24 More recent studies indicate that 
the etiology of wheezing illnesses can provide additional infor-
mation about asthma risk. Respiratory syncytial virus (RSV) is 
the most common cause of bronchiolitis, and it has recently 
been appreciated that HRV infections are the second most 
common etiology. Other viruses that also are associated with 
wheezing illnesses include coronaviruses, parainfluenzavirus-
es, metapneumoviruses, adenoviruses, and infections with 
multiple viruses. Long term follow-up of infants with bronchi-
olitis provided evidence that bronchiolitis caused by HRV in-
fections was associated with a greater risk of wheeze compared 
to RSV bronchiolitis,
25 and this association was confirmed in 
two ongoing birth cohort studies.
25,26 In the Childhood Origins 
of ASThma (COAST) cohort study, HRV wheezing illnesses in 
the first three years was associated with a significantly greater 
risk for asthma at age 6 (odd ratio [OR]=9.8) compared to in-
fants who wheezed with RSV (OR=2.6).
26 In the Childhood 
Asthma Study (CAS) conducted in Perth Australia, the risk of 
asthma at the age of 5 was increased for infants who developed 
wheezing illnesses with either HRV or RSV. The risk of develop-
ing asthma was greatest for infants who wheezed and also de-
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Figure.  Mechanisms of rhinovirus-induced airway inflammation. Human rhinovirus binds to ICAM-1 and other receptors to begin the replication cycle. Viral infec-
tions induce a variety of mediators, cytokines, and chemokines from epithelial cells and airway leukocytes that initiate an inflammatory response, including chemo-
taxis of neutrophils, and eosinophils. An antiviral response is also mounted by both epithelial and dendritic cells, producing type I interferons (IFNs). Airway eosino-
phils and allergic sensitization are risk factors for more severe rhinovirus illnesses, possibly by suppressing antiviral responses, which may be deficient in asthma.
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veloped allergen sensitization before 2 years of age.
27 These 
findings provide convincing evidence that wheezing with HRV 
infections in infancy is a strong risk factor for asthma, and in 
addition, allergic sensitization and viral wheezing both contrib-
ute to asthma risk.
Whether viral infections actually cause asthma is still hotly de-
bated. It is clear that some risk factors for viral wheezing are 
also risk factors for asthma. For example, low lung function in 
infancy has been linked to both of these outcomes. On the oth-
er hand, recurrent viral lower respiratory illness in infancy could 
damage the lower airways, and the ensuing inflammatory and 
repair processes could lead to remodeling of airway structures 
to promote chronic airway obstruction and asthma.
28-30 Studies 
are underway to better delineate risk factors for viral wheezing 
and the relationship of acute viral wheeze to chronic changes in 
airway structure and function.
31
HRV AND EXACERBATIONS OF ASTHMA
HRV-induced interferon responses are important contribu-
tors to the early innate response to infection. In asthma, HRV-
induced secretion of type I and III IFN secretion may be im-
paired, leading to more severe infection and a more prolonged 
inflammatory response.
32,33 During exacerbations, there is also 
evidence that neutrophilic responses to viral infection may be 
enhanced,
34 especially in the lower airways. Increased severity 
of infection, or a greater inflammatory response to infection, 
could ultimately lead to airway edema and respiratory smooth 
muscle contraction which consequently aggravate asthma.
17 In 
addition, there is epidemiologic evidence that synergistic inter-
actions between allergy and viral infection promote wheeze,
35,36 
and several mechanisms have been proposed to explain this ef-
fect. For example, the Th2 cytokine IL-4 greatly enhances HRV-
induced secretion of thymic stromal lymphopoietin in cultured 
epithelial cells.
37 This cytokine has been linked to the amplifica-
tion of allergic inflammatory responses. Moreover, engagement 
of high affinity IgE receptors on plasmacytoid dendritic cells in-
hibits the ability of these cells to produce interferons in response 
to respiratory viruses.
38 These experimental findings provide 
plausible mechanisms for interactions between viral infections 
and allergic mechanisms in the pathogenesis of HRV-induced 
wheezing illnesses.
TREATMENT OF VIRUS INDUCED ASTHMA
Medications including first generation antihistamines and 
nonsteroidal anti-inflammatory agents are commonly used to 
alleviate the symptoms of viral infection. Unfortunately, these 
agents do not decrease duration of symptoms or affect the nat-
ural history of cold symptoms.
39,40 As discussed earlier in this re-
view, HRV infections induce numerous cytokines and chemo-
kines that cause airway inflammation and it is likely that the vi-
rus-induced inflammation contributes to cold symptoms.
5,19 
Based on these findings, studies have been conducted to deter-
mine whether anti-inflammatory medications can be used to 
lessen cold symptoms or virus-induced exacerbations of asth-
ma.
9,40,41 Corticosteroids administered either topically or system-
ically do not affect the course of illness produced by experimen-
tal infection with HRV. In contrast, there are in vitro data to sug-
gest that the combination of fluticasone and salmeterol reduc-
es virus-induced inflammatory responses, including neutrophil 
and lymphocyte chemokine secretion by airway epithelial 
cells.
41,42
Treatment of infants with recurrent viral wheezing has yield-
ed mixed results. Regular use of inhaled corticosteroid reduces 
daily symptoms and has modest effects on the number of wheez-
ing episodes, although temporary slowing of growth has been 
observed.
43,44 One study of infants hospitalized for wheezing 
found that infants with HRV infections had a distinct response 
to treatment with systemic corticosteroid.
43 Compared to place-
bo, corticosteroid treatment had no beneficial effects noted 
during the acute illness, but children who were hospitalized 
with HRV infections and treated with corticosteroid were less 
likely to develop recurrent wheezing episodes. The latter effect 
was not observed in children who had RSV infections. In other 
reports montelukast prevented acute wheezing episodes in 
children during seasons of high viral prevalence.
41,45,46 In chil-
dren with moderate to severe asthma, the addition of omali-
zumab to standard asthma therapy reduced asthma exacerba-
tions, including those associated with viral infections.
47 Nota-
bly, omalizumab treatment eliminated the rise in spring and 
fall asthma exacerbations, which are often caused by infections 
with HRV. More clinical data are needed to clarify the utility of 
anti-inflammatory medications in the prevention or treatment 
of virus-induced wheezing episodes.
CONCLUSIONS
New findings from clinical research studies indicate that HRV 
infections are the most common cause of wheezing illnesses in 
children with asthma. There are also indications that recurrent 
HRV lower respiratory infections could promote the develop-
ment of asthma in some infants. Advances in HRV genetics to-
gether with more sophisticated murine and in vitro models of 
infection raise have provided new insights into HRV molecular 
virology and host-virus interactions. Collectively, these new 
models are expected to contribute not only to understanding 
the pathogenesis of HRV-induced exacerbations of asthma, but 
also clarify the potential role for HRV infection as a risk factor 
for asthma development.
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